menu search

Ubisoft tipped for a boost, if thursday's update confirms pipeline is on-track

Ubisoft's investment appeal is “compelling at current levels”, according to analysts at Wedbush, who repeated an ‘outperform' rating ahead of ...

October 23, 2023, 10:59 am

Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progress...

October 22, 2023, 11:00 am

Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...

October 21, 2023, 3:31 pm

Gold price forecast: $1,860-$1,960 range to hold amid slightly heightened volatility – ocbc

In the interim, geopolitical situation in Israel-Hamas should pose two-way risks to Gold prices. Escala...

October 19, 2023, 3:44 pm

Excision biotherapeutics announces presentation of interim clinical data for ebt-101 in latent hiv at upcoming european society of gene and cell therapy (esgct) 2023 annual congress

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based thera...

October 19, 2023, 11:50 am

Location, location, location: bradda head's ian stalker talks lithium in the usa

It may turn out that Ian Stalker is only in an executive role at Bradda Head for a short period of time. Certainly, the announcement of his assumption...

October 19, 2023, 8:05 am

Whitbread results pave way for further upgrades, says city analysts

Whitbread PLC (LSE:WTB) impressed at its interims and the results have gone down well in the City with...

October 18, 2023, 8:34 am

Hipgnosis songs fund meeting to face objections from major shareholders

Analysts and a major investor say that the upcoming Hipgnosis Songs Fund Limited (LSE:SONG) shareholder meeting might echo the Ella Fitzgerald song ...

October 17, 2023, 9:56 am

Can wework's new permanent ceo save we stock?

WeWork (NYSE: WE ) stock rose after naming board member David Tolley its permanent CEO. Tolley had been inter...

October 16, 2023, 10:42 am

Wework appoints david tolley as permanent chief executive

WeWork Inc (NYSE:WE) has appointed David Tolley as its new chief executive officer. Tolley has been on the WeWork board since February and has been ...

October 16, 2023, 9:13 am

Wework makes david tolley permanent ceo

WeWork Inc. WE, +3.96% said Monday it has promoted interim Chief Executive David Tolley to the role of ...

October 16, 2023, 8:39 am

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm


Search within

Pages Search Results: